BACKGROUND: Multiple partial breast radiotherapy techniques are available. We have previously presented the technical details of our procedure of delivering partial breast irradiation with a single fraction of intraoperative radiotherapy (IORT) targeting the tumor in situ prior to partial mastectomy. This study details our completed, single-institution trial. MATERIALS AND METHODS: An IRB-approved, DSMB-monitored phase II trial was performed with the following inclusion criteria: women age ≥48, ultrasound-visible invasive ductal cancers <3 cm, clinically negative axillary nodes. IORT was delivered using mobile electron irradiator, at least a 1.5-cm radial and 1-cm deep margin; patients received 15 Gy and immediately underwent partial mastectomy. Ipsilateral breast recurrence was classified as true/marginal, elsewhere in the breast or nodal basin. Kaplan-Meier methods were used to estimate survival functions and exact 95% confidence intervals are reported. RESULTS: Between 2003 and 2007, 71 women underwent IORT (median follow-up: 3.5 years). For patients with tumor-involved or close margins, additional therapy was required: 7 patients, total mastectomy; 11, whole breast radiation. Four women experienced invasive ipsilateral breast failures (1 new primary, 3 margin recurrences) for a 3-year local control rate of 49 of 53 (94.8%; 95% confidence interval 92.4% [95% CI] 84.2–98.3%), actuarial three-year in breast recurrence was 8% (95% CI 2–18%), and breast cancer-specific survival was 100%. CONCLUSIONS: Intraoperative radiotherapy delivered to an in situ tumor is feasible, but our local control rate at 3.5 years is concerning. Possible changes to this technique to improve local control rates include better preoperative imaging (MRI), routine intraoperative ultrasound, and improved IORT delivery (larger cone, increased dose).
BACKGROUND: Multiple partial breast radiotherapy techniques are available. We have previously presented the technical details of our procedure of delivering partial breast irradiation with a single fraction of intraoperative radiotherapy (IORT) targeting the tumor in situ prior to partial mastectomy. This study details our completed, single-institution trial. MATERIALS AND METHODS: An IRB-approved, DSMB-monitored phase II trial was performed with the following inclusion criteria: women age ≥48, ultrasound-visible invasive ductal cancers <3 cm, clinically negative axillary nodes. IORT was delivered using mobile electron irradiator, at least a 1.5-cm radial and 1-cm deep margin; patients received 15 Gy and immediately underwent partial mastectomy. Ipsilateral breast recurrence was classified as true/marginal, elsewhere in the breast or nodal basin. Kaplan-Meier methods were used to estimate survival functions and exact 95% confidence intervals are reported. RESULTS: Between 2003 and 2007, 71 women underwent IORT (median follow-up: 3.5 years). For patients with tumor-involved or close margins, additional therapy was required: 7 patients, total mastectomy; 11, whole breast radiation. Four women experienced invasive ipsilateral breast failures (1 new primary, 3 margin recurrences) for a 3-year local control rate of 49 of 53 (94.8%; 95% confidence interval 92.4% [95% CI] 84.2–98.3%), actuarial three-year in breast recurrence was 8% (95% CI 2–18%), and breast cancer-specific survival was 100%. CONCLUSIONS: Intraoperative radiotherapy delivered to an in situ tumor is feasible, but our local control rate at 3.5 years is concerning. Possible changes to this technique to improve local control rates include betterpreoperative imaging (MRI), routine intraoperative ultrasound, and improved IORT delivery (larger cone, increased dose).
Authors: J S Mandelblatt; J Hadley; J F Kerner; K A Schulman; K Gold; J Dunmore-Griffith; S Edge; E Guadagnoli; J J Lynch; N J Meropol; J C Weeks; R Winn Journal: Cancer Date: 2000-08-01 Impact factor: 6.860
Authors: David E Wazer; Seth Kaufman; Laurie Cuttino; Thomas DiPetrillo; Douglas W Arthur Journal: Int J Radiat Oncol Biol Phys Date: 2005-10-24 Impact factor: 7.038
Authors: L S McGinnis; H R Menck; H J Eyre; K I Bland; C E Scott-Conner; M Morrow; D P Winchester Journal: Cancer Date: 2000-02-15 Impact factor: 6.860
Authors: Kandace P McGuire; Alfredo A Santillan; Paramjeet Kaur; Tammi Meade; Jateen Parbhoo; Morgan Mathias; Corinne Shamehdi; Michelle Davis; Daniel Ramos; Charles E Cox Journal: Ann Surg Oncol Date: 2009-08-04 Impact factor: 5.344
Authors: Barbara Belletti; Jayant S Vaidya; Sara D'Andrea; Frank Entschladen; Mario Roncadin; Francesca Lovat; Stefania Berton; Tiziana Perin; Ezio Candiani; Sonia Reccanello; Andrea Veronesi; Vincenzo Canzonieri; Mauro G Trovò; Kurt S Zaenker; Alfonso Colombatti; Gustavo Baldassarre; Samuele Massarut Journal: Clin Cancer Res Date: 2008-03-01 Impact factor: 12.531
Authors: Sarah T Hawley; Jennifer J Griggs; Ann S Hamilton; John J Graff; Nancy K Janz; Monica Morrow; Reshma Jagsi; Barbara Salem; Steven J Katz Journal: J Natl Cancer Inst Date: 2009-08-31 Impact factor: 13.506
Authors: Noam A Vanderwalde; Ellen L Jones; Randall J Kimple; Dominic T Moore; Nancy Klauber-Demore; Carolyn I Sartor; David W Ollila Journal: Cancer Date: 2013-01-29 Impact factor: 6.860